A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma

Haematologica

Volumn 89, Issue 5, 2004, Pages 552-556

  Brenne, Anne Tove ^a   Romstad, Lene Hejna ^a   Gimsing, Peter ^b   Juliusson, Gunnar ^c   Turesson, Ingemar ^d   Romundstad, Pål ^a   Borset, Magne ^a   Sundan, Anders ^a   Waage, Anders ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Rigshospitalet   (Denmark)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Advanced myeloma; Soluble TNFR; Thalidomide

Indexed keywords

PROTEIN P55; THALIDOMIDE; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; SERUM; TREATMENT OUTCOME;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SURVIVAL RATE; THALIDOMIDE;

EID: 2542468811     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
2. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
3. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999;163:380-6.
4. +) T cells. Clin Exp Immunol 2002;130:75-84.
5. Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM. Cytokines (IL-6, TNF-α, IL-1α) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prev 1996;20:52-6.
6. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:3127-31.
7. Bjornberg F, Lantz M, Gullberg U. Metalloproteases and serineproteases are involved in the cleavage of the two tumour necrosis factor (TNF) receptors to soluble forms in the myeloid cell lines U-937 and THP-1. Scand J Immunol 1995;42:418-24.
8. Katsura K, Park M, Gatanaga M, Yu EC, Takishima K, Granger GA, et al. Identification of the proteolytic enzyme which cleaves human p75 TNF receptor in vitro. Biochem Biophys Res Commun 1996;222:298-302.
9. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-9.
10. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
11. Lantz M, Malik S, Slevin ML, Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990;2:402-6.
12. Liabakk NB, Sundan A, Lien E, Laegreid A, Bombara MP, Ranges G, et al. The release of soluble p55 TNF receptor from U937 cells studied by a new p55 immunoassay. J Immunol Methods 1993;163:145-54.
13. Lien E, Liabakk NB, Johnsen AC, Nonstad U, Sundan A, Espevik T. Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur J Immunol 1995;25:2714-7.
14. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230-5.
15. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986;5:255-60.
16. Borset M, Medvedev AE, Sundan A, Espevik T. The role of the two TNF receptors in proliferation, NF-κ B activation and discrimination between TNF and LT α signalling in the human myeloma cell line OH-2. Cytokine 1996;8:430-8.
17. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS, Jr. Inhibition of NF-κ B activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 2001;276:22382-7.
18. Hale KK, Smith CG, Baker SL, Vanderslice RW, Squires CH, Gleason TM, et al. Multifunctional regulation of the biological effects of TNF-α by the soluble type I and type II TNF receptors. Cytokine 1995;7:26-38.
19. Froon AH, Bemelmans MH, Greve JW, van der Linden CJ, Buurman WA. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med 1994;22:803-9.
20. Iglesias J, Marik PE, Levine JS. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-α as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 2003;41:62-75.
21. Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 1998;77:2357-62.
22. Vinante F, Rigo A, Tecchio C, Morosato L, Nadali G, Ricetti MM, et al. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome. Br J Haematol 1998;102:1025-34.
23. Wu S, Korte A, Gessner R, Henze G, Seeger K. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence. Cancer 2003;98:625-31.
24. Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, et al. Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 2002;100:2263-5.
25. Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R, et al. Plasma levels of tumour necrosis factor α and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol 2003;123:305-8.